| Literature DB >> 19351315 |
Asha C Bowen1, Mark J Ferson, Linda V Graudins, Pamela Palasanthiran.
Abstract
Azithromycin is recommended as the first-line antibiotic for the prophylaxis and treatment of pertussis, a common vaccine-preventable communicable disease. Azithromycin is better tolerated than other macrolide antibiotics. Access to azithromycin is limited, as the product information and the Pharmaceutical Benefits Scheme do not include azithromycin for pertussis. Issues regarding access to azithromycin are highlighted in a case report of pertussis exposure in a tertiary paediatric hospital.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19351315 DOI： 10.5694/j.1326-5377.2009.tb02455.x
Source DB: PubMed Journal: Med J Aust ISSN： 0025-729X Impact factor: 7.738